Currently, the most commonly used treatment of NSCLC is molecular targeted drugs targeting at mutations of epidermic growth factor receptor (EGFR), also known as small‐molecule tyrosine kinase inhibitors (TKIs), which have obvious clinical efficacy on NSCLC patients with EGFR sensitive mutations.11 This evidence concerns the gene EGFR and non-small cell lung carcinoma.